Abbott U.S. Pharma Head Is Goffredo: Higgins Becomes Enzon CEO
Executive Summary
Abbott's U.S. pharmaceutical business will be headed by former VP-European Operations David Goffredo following the departure of Senior VP-Pharmaceutical Operations Arthur Higgins to become CEO of Enzon.
You may also be interested in...
Abbott Sees Metabolic Growth In Knoll: Meridia May Mesh With TriCor
Abbott sees potential marketing synergies between the triglyceride-lowering agent TriCor (fenofibrate) and Knoll's obesity agent Meridia (sibutramine).
Abbott Goes Academic: Pharma Will Be Led By Harvard Med's Leiden
Abbott is casting aside its traditional formula for senior drug management and turning its pharmaceutical division over to the recently recruited head of research, Jeffrey Leiden, MD/PhD.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011